Skip to content

Barinthus Biotherapeutics plc.

Delisted

CIK 1828185fmd_1FD0EGRPXDQ7EMWJ733ZRG48S1Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods

Latest annual · FY2025

Millions
Total revenues
0
Operating income
(71)
Net income
(66)
Free cash flow
(48)

Latest quarter · Q2 FY2026

Millions
Operating income
(11)
Net income
(11)
Free cash flow
(8)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
n/m
Revenue, 5 yearsFY2020 to FY2025
n/m
Net income, 5 yearsFY2020 to FY2025
n/m

Barinthus Biotherapeutics plc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$0$15 million-100%10-K 2026-03-13 · proof
Operating income-$70.6 million-$68 million10-K 2026-03-13 · proof
Net income-$66.4 million-$61.1 million10-K 2026-03-13 · proof
Cash from operating activities-$48 million-$28.9 million10-K 2026-03-13 · proof
Free cash flow-$48 million-$29.8 million10-K 2026-03-13 · proof
Total assets$98.2 million$160.3 million-38.8%10-K 2026-03-13 · proof
Total liabilities$23.9 million$30.2 million-20.9%10-K 2026-03-13 · proof
Cash and cash equivalents$70.5 million$110.7 million-36.3%10-K 2026-03-13 · proof
What was Barinthus Biotherapeutics plc.'s revenue in fiscal 2025?
Barinthus Biotherapeutics plc. reported revenue of $0 for fiscal 2025 (the year ended Dec 31, 2025), against $15 million the year before (-100%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What was Barinthus Biotherapeutics plc.'s operating income in fiscal 2025?
Barinthus Biotherapeutics plc. reported operating income of -$70.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$68 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What was Barinthus Biotherapeutics plc.'s net income in fiscal 2025?
Barinthus Biotherapeutics plc. reported net income of -$66.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$61.1 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What was Barinthus Biotherapeutics plc.'s cash from operating activities in fiscal 2025?
Barinthus Biotherapeutics plc. reported cash from operating activities of -$48 million for fiscal 2025 (the year ended Dec 31, 2025), against -$28.9 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What was Barinthus Biotherapeutics plc.'s free cash flow in fiscal 2025?
Barinthus Biotherapeutics plc. reported free cash flow of -$48 million for fiscal 2025 (the year ended Dec 31, 2025), against -$29.8 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What are Barinthus Biotherapeutics plc.'s total assets?
As of Dec 31, 2025, Barinthus Biotherapeutics plc. reported total assets of $98.2 million, against $160.3 million a year earlier (-38.8%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What are Barinthus Biotherapeutics plc.'s total liabilities?
As of Dec 31, 2025, Barinthus Biotherapeutics plc. reported total liabilities of $23.9 million, against $30.2 million a year earlier (-20.9%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
What are Barinthus Biotherapeutics plc.'s cash and cash equivalents?
As of Dec 31, 2025, Barinthus Biotherapeutics plc. reported cash and cash equivalents of $70.5 million, against $110.7 million a year earlier (-36.3%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1828185&period_type=annual&limit=5"

Information only, not investment advice.